Binnopharm Group implements Good Distribution Practices (GDP)
12.01.2023
GDP is a quality assurance system for drug storage and wholesale distribution facilities. The GDP compliance ensures quality management coordination throughout the supply chain, including the supply of finished products to retailers and healthcare facilities.
Rustem Muratov, Binnopharm Group’s Chief Executive Office, said, “It is vital for the company to comply with international standards. We believe that implementing Good Distribution Practices is essential for any pharmaceutical company. The role of GDP certification is growing in drug product supply both in the territory of Russia and to foreign markets. Today, Binnopharm Group is a top Russian supplier of drugs to the neighboring countries, and we are planning to open our representative office in China this year.”
Last year was the year of expansion for Binnopharm Group, as the company opened its offices in six CIS countries: Belarus, Moldova, Azerbaijan, Armenia, Uzbekistan and Kazakhstan. Binnopharm Group ranked first in sales among all pharmaceutical companies in Kyrgyzstan. The Group operates in all segments of the pharmaceutical market and sells its products in 14 countries.
Binnopharm Group’s extensive diversified portfolio is marketed across a few distribution channels with the help of international supply management in the CIS. The Group is planning to increase its presence in other countries.
Rustem Muratov, Binnopharm Group’s Chief Executive Office, said, “It is vital for the company to comply with international standards. We believe that implementing Good Distribution Practices is essential for any pharmaceutical company. The role of GDP certification is growing in drug product supply both in the territory of Russia and to foreign markets. Today, Binnopharm Group is a top Russian supplier of drugs to the neighboring countries, and we are planning to open our representative office in China this year.”
Last year was the year of expansion for Binnopharm Group, as the company opened its offices in six CIS countries: Belarus, Moldova, Azerbaijan, Armenia, Uzbekistan and Kazakhstan. Binnopharm Group ranked first in sales among all pharmaceutical companies in Kyrgyzstan. The Group operates in all segments of the pharmaceutical market and sells its products in 14 countries.
Binnopharm Group’s extensive diversified portfolio is marketed across a few distribution channels with the help of international supply management in the CIS. The Group is planning to increase its presence in other countries.
